dolutegravir
Selected indexed studies
- Dolutegravir-associated hyperglycemia: a narrative review. (AIDS Res Ther, 2025) [PMID:41013560]
- HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. (Lancet HIV, 2023) [PMID:37832567]
- Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. (Drugs, 2020) [PMID:31865558]
_Worker-drafted node — pending editorial review._
Connections
dolutegravir is a side effect of
Sources
- Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. (2020) pubmed
- Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection. (2019) pubmed
- Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial. (2025) pubmed
- Dolutegravir/Rilpivirine: A Review in HIV-1 Infection. (2018) pubmed
- Dolutegravir-associated hyperglycemia: a narrative review. (2025) pubmed
- HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. (2023) pubmed
- Predictors of treatment-emergent resistance to dolutegravir. (2025) pubmed
- How frequent is dolutegravir resistance? (2025) pubmed
- Pharmacokinetics and placental transfer of dolutegravir in pregnancy. (2022) pubmed
- Dolutegravir: first global approval. (2013) pubmed